Passage Bio, Inc. (PASG) is a Biotechnology company in the Healthcare sector, currently trading at $10.86. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is PASG = $6 (-44.8% upside).
Valuation: PASG trades at a trailing Price-to-Earnings (P/E) of -0.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.06.
Net income is $46M (loss), growing at +30.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $24M against $19M equity (Debt-to-Equity (D/E) ratio 1.28, moderate). Current ratio is 2.07 (strong liquidity). Debt-to-assets is 38.6%. Total assets: $62M.
Analyst outlook: 7 / 9 analysts rate PASG as buy (78%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 63/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 75/100 (Pass), Moat 28/100 (Fail), Future 49/100 (Partial), Income ?/100 (Fail).
